PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2009-01-23 Wyeth Acquisition Could be Major Distraction for Pfizer Pfizer is reported to be in discussions to acquire Wyeth. The potential cost-savings could be huge, but the question is whether the merger is good for both companies in the long-term to bring blockbuster drugs through the pipeline.
- Published on: 2009-01-21 S*Bio Signs Two Major Anticancer Deals S*Bio, based in Singapore concluded two major deals for its anti-cancer drugs during January 2008; one with Onyx Pharmaceuticals for JAK2 inhibitors, SB1578 and SB1518, and the other with Tragara Pharmaceuticals for the oral multikinase inhibitor, SB1317.
- Published on: 2009-01-20 Teva’s Biosimilar Capabilities Mount with its Latest Joint Venture Teva’s biosimilar development expertise is set to increase with its latest joint venture with Swiss company, Lonza. The two companies will work together in developing and manufacturing biosimilars – whose market size is expected to surge under the new US administration. However, some big pharma companies are also making moves into the sector, thus providing Teva with stiff competition.
- Published on: 2009-01-13 ZymoGenetics in Blockbuster Deal with BMS Bristol-Myers Squibb signed a US$1.1 B deal to co-develop ZymoGenetics’ PEG-interferon lambda, a hepatitis C drug, which is in early clinical trials. ZymoGenetics needed a deal of this size for its survival whereas Bristol-Myers had to strengthen its hepatitis C pipeline.
- Published on: 2009-01-12 Wyeth Deals Signal Diversification Strategy Wyeth and Santaris have entered into an agreement to develop new drugs based on Santaris’ Locked Nucleic Acid drug platform that could treat protein-related diseases. Wyeth is diversifying into biotech and this deal adds another technology to increase the company’s capability to bring new drugs onto the market.
- Published on: 2009-01-05 Endo Diversification Leads to Indevus Buyout Endo Pharmaceuticals, the marketer of pain medications, has reached an agreement to acquire Indevus Pharmaceuticals in a deal that is intended to bolster its pipeline and expand its business beyond pain therapy. Indevus specialises in urology and endocrinology and has two products awaiting approval.
- Published on: 2008-12-30 Synta Seals Deal in Inflammatory Diseases with Roche Synta Pharmaceuticals has entered into a partnership with Roche to discover and develop small molecules that target CRACM channels implicated in various inflammatory diseases. Although this is only the second major agreement signed by Synta, it could prove to be its most rewarding should the partners succeed in developing a drug with disease-modifying attributes against inflammatory conditions.
- Published on: 2008-12-17 Dynavax’s Deal Termination with Merck is followed by a New Agreement with GSK The US biotech, Dynavax, has become the latest company to enter into an option agreement with GlaxoSmithKline. This comes as a boost to the company following the termination of its agreement with Merck for its most advanced product – the Hepatitis B vaccine, Heplisav.
- Published on: 2008-12-17 Pfizer Gains European Rights to Specialist Biologic Product, Xiaflex Pfizer has gained European rights to Auxilium Pharmaceuticals’ Xiaflex™ (clostridial collagenase for injection) – a novel, first-in-class, late-stage biologic, for the treatment of Dupuytren's contracture and Peyronie's disease. There is a growing trend for Big Pharma to build up their specialty care product portfolio, illustrated by the multiple offers that Auxilium says it received for Xiaflex.
- Published on: 2008-12-15 Teva Invests in Yeast-based Drug Discovery Technology Teva has entered into an agreement with Yissum, the Hebrew University of Jerusalem technology transfer company, to finance a yeast-based drug discovery technology developed by Jexys, a Yissum subsidiary. This early investment highlights Teva’s confidence in the technology and supports Teva’s efforts to boost its activity within proprietary drug development.
Last Issue PDF
RSS